All News
Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels
Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc.
AE trended higher in normal CRP pts taking Tofa compared to placebo
@RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa
Robert B Chao, MD ( View Tweet)
Long term safety data for bimekizumab (IL17i) in Psa & axSpA
Overall as expected; increased infections (esp fungal/candida) & hepatic events
No new signals... uveitis flares is interesting
Need H2H of IL17's! IXE vs SEC vs BIM
@RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA
Mike Putman EBRheum ( View Tweet)
Are anti CCP3 the new anti CCP2 antibodies?
Not yet!
Anti-CCP3 associated w/ diagnosis of RA in a population of patients w/ MSK symptoms
But… very strong overlap between CCP2 and 3 with only 3.4% positive for CCP3 negative for CCP2
@RheumNow #ACR23 ABST 0389 https://t.co/BHRqCbqEYw
Aurelie Najm ( View Tweet)
Detectable hs-cTnT at baseline was associated with future MACE HR 5.6, in the hsCRP high→low cohort with high inflammation at baseline, not vice versa. hs-cTnT may provide additional info for assessing CV risk, Weber et al, Abst#0387 https://t.co/M4zyz2tzIO #ACR23 @RheumNow https://t.co/omMgpRzBA5
Dr. Antoni Chan ( View Tweet)
Does pregnancy affect axSpA imaging?
Large study of 381 pts, in the DESIR cohort, f/up of 5 years.
Pregnancy did not aggravate imaging of axSpA women compared to prior to pregnancy.
@RheumNow #ACR23 Abs#0513 https://t.co/eeGuxGGB5E
Robert B Chao, MD ( View Tweet)
#ACR23 Abs 0465 suggests changes in rheums’ rx patterns in context of nationwide abortion restriction, particularly in abortion-restricted states; reproductive-age female pts may have less access to EB treatments like MTX/MMF for rheum dz. https://t.co/QN9C4PjUaN
@rheumnow
Dr. Rachel Tate ( View Tweet)
Non invasive screening for pulmonary involvement in early RA
Combination of PFT and Lung 🫁 US:
-50% with interstitial or focal changes or pleural effusion on US
-58% with abnormal DLCO
Correlation w/ higher disease activity.
Pathological meaning?
@RheumNow ABST 0393 #ACR23 https://t.co/BBcOEgcJK2
Aurelie Najm ( View Tweet)
@RheumNow PMR Mythbusters:
we polled Aussie🇦🇺 rheumatologists
How did those motivated enough to answer a PMR/GCA survey fare?
Myth: PMR is only proximal
- not bad
Myth: PMR needs ⬆️ESR/CRP
- a bit of work
Time to #MakeRheumForPMR
@victor_yang1 @CatherineL_Hill #ACR23 ABST0267 https://t.co/Z4ZkDHljOf https://t.co/ssHxOBJFxR
David Liew drdavidliew ( View Tweet)
WEAR study: adherence to wearable activity trackers in RA
Something that is consistent across all wearable studies is low adherence
Here under 50% for PRO + tracking
In an already selected population!
To implement, we need to make this better?
ABSTRACT 0344 @RheumNow #ACR23 https://t.co/csVZlzABGt
Aurelie Najm ( View Tweet)
Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A
Dr. Antoni Chan ( View Tweet)
Deucravacitinib (TYK2) data has been surprisngly good in SLE
Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL
Probably my #1 draft pick for "drugs I'm buying right now"
@RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp
Mike Putman EBRheum ( View Tweet)
Year in Review: Dr. P Seo
⭐️Does Pizza consumption favor improved dz activity in RA?
If in Italy
➡️ 365 pts w/RA in Milan: 18-65 yo w/ >3 mo dz
➡️Ate 1/2 a pizza > 1x/wk w/ decr in dz activity (SDAI⬇️: -3.6)
➡️Mozzarella & olive oil showed beneficial effects
#ACR23 @RheumNow https://t.co/qZTzThI39e
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
YR in Review: Dr. P Seo
⭐️Sarilumab for relapse of PMR during GC taper:
➡️ab against IL6R
➡️118 pts:
⏺️pred 15 mg/d
⏺️Sari 200 mg/d q2wk/14wk
⏺️52wk pred taper
➡️At wk 52:
⏺️sustained remission: 28% vs 10%
⏺️mean total GC: 777 vs 2044 mg
#ACR23 @RheumNow https://t.co/ETVpyuBlZ7
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Towards more personalised care in rheumatoid arthritis #ACR23 @RheumNow https://t.co/roxtcX8QHI
Dr. Antoni Chan ( View Tweet)
There is a high concordance (84.4%) of physician and patient global assessment of psoriatic arthritis disease activity from 538 paired assessments in the ARLAR multinational study, Maroof A et al, Abst #0506 #ACR23 @RheumNow https://t.co/NsT4MNWPVX https://t.co/TfuMj8qMXz
Dr. Antoni Chan ( View Tweet)
RA as a young woman used to mean kids were only a distant thought.
Japanese RA pts n=280 asked whether RA onset meant wanting fewer children & why.
Confidence improving across the board over time.
We want to give our RA pts choices to live their life!
#ACR23 ABST0473 @RheumNow https://t.co/OHZM2J5qxS
David Liew drdavidliew ( View Tweet)
Tired of getting referrals for symptomatic patients with 1/80+ ANAs antibodies?
This new risk model for systemic AID is very welcome!
Variables: age, female, higher ANA titer, higher platelet count, disease-specific autoantibody & billing code count.
#ACR23 @Rheumnow ABST0131 https://t.co/q8rYjjtZ89
Aurelie Najm ( View Tweet)
Year in Review: Dr. P Seo
Dr. Seo gave a moment of silence to Baricitinib use in SLE given studies showing it is not efficacious for SLE
#ACR23 @RheumNow https://t.co/8GKUlfJdbe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Year in Review: Dr. P Seo
Novel PsA therapy on the horizon:
⭐️Bimekizumab
➡️ Anti-IL17A, ANti-IL17F ab
🚩BE COMPLETE
➡️ TNFi failures
➡️Phase III, 400 pts, bimekizumab, PBO
➡️ Wk 16: improvements in joint and skin
#ACR23 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Year in Review: Dr. P Seo
Novel PsA therapy on the horizon:
⭐️Bimekizumab
➡️ Anti-IL17A, ANti-IL17F ab
🚩BE OPTIMAL
➡️ tx-naive
➡️Phase III, 852 pts, bimekizumab, PBO, ADA
➡️ Wk 16: same as ADA for joints, BETTER FOR SKIN
#ACR23 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)